Table 1.
Baseline characteristics of included cases and controls according to randomization group
| HBV and/or HCV coinfected |
HIV monoinfected controls |
||||||
|---|---|---|---|---|---|---|---|
| DC (n=347) |
VS (n=328) |
Total (n=675) |
DC (n=347) |
VS (n=327) |
Total (n=674) |
P-value* | |
| HBV infection (%) | 17.6 | 14.9 | 16.3 | 0 | 0 | 0 | NA |
| HCV infection (%) | 81.0 | 82.9 | 81.9 | 0 | 0 | 0 | NA |
| HBV and HCV infection (%) | 1.4 | 2.1 | 1.8 | 0 | 0 | 0 | NA |
| Age, median years (IQR) | 45 (40, 51) | 45 (41, 50) | 45 (40, 50) | 44 (40, 51) | 44 (40, 50) | 44 (40, 51) | NA |
| Female sex (%) | 26.5 | 24.4 | 25.5 | 26.5 | 24.5 | 25.5 | NA |
| Black race (%) | 48.7 | 48.2 | 48.4 | 33.1 | 35.2 | 34.1 | <0.0001 |
| History of alcohol abuse (%) | 25.9 | 25.0 | 25.5 | 25.9 | 24.8 | 25.4 | NA |
| Intravenous drug use as mode of HIV transmission (%) | 49.9 | 52.1 | 51.0 | 2.0 | 3.4 | 2.7 | <0.0001 |
| Baseline CD4+ count, median cells/µL (IQR) | 599 (462, 759) | 566 (459, 702) | 580 (460, 736) | 567 (464, 800) | 599 (476, 823) | 583 (470, 803) | 0.17 |
| Nadir CD4+ count, median cells/µL (IQR) | 232 (131, 343) | 248 (145, 379) | 240 (134, 361) | 248 (131, 375) | 240 (150, 350) | 244 (148, 358) | 0.80 |
| HIV RNA ≤ 400 copies/mL (%) | 67.6 | 60.4 | 64.1 | 65.1 | 69.4 | 67.2 | 0.24 |
| Prior diagnosis of AIDS (%) | 30.0 | 29.0 | 29.5 | 29.1 | 26.6 | 27.9 | 0.52 |
| Antiretroviral therapy naïve (%) | 1.2 | 3.7 | 2.4 | 5.8 | 2.8 | 4.3 | 0.05 |
| On antiretroviral therapy (%) | 81.8 | 76.5 | 79.3 | 84.1 | 87.5 | 85.8 | 0.002 |
| Time since initiation of ART, median years (IQR) | 7 (5, 9) | 6 (4, 9) | 7 (4, 9) | 5 (3, 8) | 7 (4, 9) | 6 (3, 9) | 0.001 |
| Hyaluronic acid level, median ng/mL (IQR) | 29.0 (16.4, 54.1) | 30.9 (18.2, 59.1) | 29.7 (17.3, 55.9) | 18.8 (11.0, 30.2) | 18.9 (11.8, 29.7) | 18.9 (11.5, 30.2) | <0.0001 |
| Hyaluronic acid >75 ng/mL (%) | 17.6 | 18.9 | 18.2 | 3.2 | 1.5 | 2.4 | <0.0001 |
DC: drug conservation, VS: viral suppression, IQR: interquartile range, ART: antiretroviral therapy
*
p-value compares HCV/HBV coinfected participants to HIV monoinfected participants. (NA: not applicable)